Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Peter Halling | President & CEO | 2.03M | -- | 1977 |
| Mr. Claus Steensen Solje | Executive VP, CFO & Member of Management Board | 979.39k | -- | 1972 |
| Mr. Søren Daniel Niegel | Executive VP of Commercial Operations & Member of Management Board | 852.03k | -- | 1971 |
| Dr. Henriette Mersebach | Executive VP Research & Development & Member of Management Board | 736.32k | -- | 1971 |
| Ms. Katja Barnkob Thalund | Senior Project Director, Global Clinical Development & Employee-elected Director | 46.92k | -- | 1969 |
| Ms. Lise Lund Maerkedahl | Project Director of Global Research & Employee-elected Director | 46.92k | -- | 1967 |
| Mr. Per Plotnikof | VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR | -- | -- | -- |
| Jacob Glenting | Senior Vice President of Global Strategy & Corporate Development | -- | -- | 1974 |
| Ms. Lika Thiesen | Executive Vice President of Global People & Organisation | -- | -- | 1975 |
| Prof. Hendrik Kees Kam Nolte M.D., Ph.D. | Senior Vice President of Research & Development - North America and International Markets | -- | -- | -- |
ALK-Abelló A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2,753
Description
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that provide support, guidance, and relief, as well as smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. It has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX, a grass pollen allergy tablet; CEDARCURE, a tablet for the treatment of Japanese cedar pollen induced allergy; and MITICURE for the treatment of house dust mite-induced allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Corporate Governance
Upcoming Events
May 6, 2025 at 10:59 AM UTC
ALK-Abelló A/S Earnings Date
Recent Events
March 16, 2017 at 12:00 AM UTC
Ex-Dividend Date